Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Lowers EPS Guidance On Plavix Decision

This article was originally published in The Pink Sheet Daily

Executive Summary

Bristol-Myers Squibb downgraded its full year eps guidance by up to 24% based on the impact of Apotex' launch of generic clopidogrel.

You may also be interested in...



Bristol Plans Plavix Price Increase Next Year

Bristol-Myers Squibb is supporting Plavix "full steam" with DTC ads to mitigate impact from generic clopidogrel.

Bristol Plans Plavix Price Increase Next Year

Bristol-Myers Squibb is supporting Plavix "full steam" with DTC ads to mitigate impact from generic clopidogrel.

Bristol’s Termination Of Dolan Follows Federal Monitor’s Recommendation

However, the company’s monitor and the U.S. Attorney for New Jersey conclude that Bristol has not violated a deferred prosecution agreement.

Topics

UsernamePublicRestriction

Register

OM013202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel